HC Wainwright Analysts Lower Earnings Estimates for ETON

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – HC Wainwright reduced their Q2 2025 EPS estimates for shares of Eton Pharmaceuticals in a note issued to investors on Wednesday, March 19th. HC Wainwright analyst S. Ramakanth now expects that the company will earn $0.08 per share for the quarter, down from their prior estimate of $0.17. HC Wainwright currently has a “Buy” rating and a $33.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.42 EPS, FY2026 earnings at $1.57 EPS, FY2027 earnings at $1.85 EPS, FY2028 earnings at $2.87 EPS and FY2029 earnings at $3.74 EPS.

Several other research analysts have also recently weighed in on the stock. B. Riley reissued a “buy” rating and issued a $24.00 price target (up from $21.00) on shares of Eton Pharmaceuticals in a report on Wednesday. Craig Hallum increased their price target on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday.

Eton Pharmaceuticals Stock Performance

Shares of ETON stock opened at $14.22 on Friday. The firm’s 50-day moving average is $15.58 and its 200-day moving average is $11.58. The stock has a market cap of $370.45 million, a price-to-earnings ratio of -64.64 and a beta of 1.37. Eton Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $18.41.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.02). The company had revenue of $11.65 million for the quarter, compared to analysts’ expectations of $10.53 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Eton Pharmaceuticals by 86.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after purchasing an additional 30,167 shares during the period. Wasatch Advisors LP bought a new position in shares of Eton Pharmaceuticals during the third quarter worth approximately $1,431,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Eton Pharmaceuticals during the third quarter worth approximately $54,000. Parkman Healthcare Partners LLC increased its holdings in shares of Eton Pharmaceuticals by 2.8% during the third quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock worth $1,561,000 after purchasing an additional 7,029 shares during the period. Finally, Jane Street Group LLC bought a new position in shares of Eton Pharmaceuticals during the third quarter worth approximately $90,000. 27.86% of the stock is owned by institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.